Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.

Glucocorticoid induced osteoporosis (GIO) is associated with an increase in bone marrow adiposity which skews the differentiation of mesenchymal stem cell (MSC) progenitors away from osteoblastogenesis and towards adipogenesis. We have previously found that vanadate, a non-specific protein tyrosine...

Full description

Bibliographic Details
Main Authors: Frans Alexander Jacobs, Hanel Sadie-Van Gijsen, Mari van de Vyver, William Frank Ferris
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-08-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00108/full
_version_ 1819208088308154368
author Frans Alexander Jacobs
Hanel Sadie-Van Gijsen
Mari van de Vyver
William Frank Ferris
author_facet Frans Alexander Jacobs
Hanel Sadie-Van Gijsen
Mari van de Vyver
William Frank Ferris
author_sort Frans Alexander Jacobs
collection DOAJ
description Glucocorticoid induced osteoporosis (GIO) is associated with an increase in bone marrow adiposity which skews the differentiation of mesenchymal stem cell (MSC) progenitors away from osteoblastogenesis and towards adipogenesis. We have previously found that vanadate, a non-specific protein tyrosine phosphatase inhibitor, prevents GIO in rats, but it was unclear whether vanadate directly influenced adipogenesis in bone-derived MSCs. For the present study, we investigated the effect of vanadate on adipogenesis in primary rat MSCs derived from bone marrow (bmMSCs) and from the proximal end of the femur (pfMSCs). By passage 3 after isolation, both cell populations expressed the MSC cell surface markers CD90 and CD106, but not the haematopoietic marker CD45. However, although variable, expression of the fibroblast marker CD26 was higher in pfMSCs than in bmMSCs. Differentiation studies using osteogenic and adipogenic induction media (OM and AM, respectively) demonstrated that pfMSCs rapidly accumulated lipid droplets within 1 week of exposure to AM, while bmMSCs isolated from the same femur only formed lipid droplets after 3 weeks of AM treatment. Conversely, pfMSCs exposed to OM produced mineralized extracellular matrix (ECM) after 3 weeks, compared to 1 week for OM-treated bmMSCs. Vanadate (10 µM) added to AM resulted in a significant reduction in AM-induced intracellular lipid accumulation and expression of adipogenic gene markers (PPARγ2, aP2, adipsin) in both pfMSCs and bmMSCs. Pharmacological concentrations of glucocorticoids (1 µM) alone did not induce lipid accumulation in either bmMSCs or pfMSCs, but resulted in significant cell death in pfMSCs. Our findings demonstrate the existence of at least two fundamentally different MSC depots within the femur, and highlights the presence of MSCs capable of rapid adipogenesis within the proximal femur, an area prone to osteoporotic fractures. In addition, our results suggest that the increased bone marrow adiposity observed in GIO may not be solely due to direct effect of glucocorticoids on bone-derived MSCs, and that an increase in femur lipid content may also arise from increased adipogenesis in MSCs residing outside of the bone marrow niche.
first_indexed 2024-12-23T05:33:49Z
format Article
id doaj.art-14a97e272f4d401e85068e30fb60d601
institution Directory Open Access Journal
issn 1664-2392
language English
last_indexed 2024-12-23T05:33:49Z
publishDate 2016-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj.art-14a97e272f4d401e85068e30fb60d6012022-12-21T17:58:23ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922016-08-01710.3389/fendo.2016.00108207329Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.Frans Alexander Jacobs0Hanel Sadie-Van Gijsen1Mari van de Vyver2William Frank Ferris3Stellenbosch UniversityStellenbosch UniversityStellenbosch UniversityStellenbosch UniversityGlucocorticoid induced osteoporosis (GIO) is associated with an increase in bone marrow adiposity which skews the differentiation of mesenchymal stem cell (MSC) progenitors away from osteoblastogenesis and towards adipogenesis. We have previously found that vanadate, a non-specific protein tyrosine phosphatase inhibitor, prevents GIO in rats, but it was unclear whether vanadate directly influenced adipogenesis in bone-derived MSCs. For the present study, we investigated the effect of vanadate on adipogenesis in primary rat MSCs derived from bone marrow (bmMSCs) and from the proximal end of the femur (pfMSCs). By passage 3 after isolation, both cell populations expressed the MSC cell surface markers CD90 and CD106, but not the haematopoietic marker CD45. However, although variable, expression of the fibroblast marker CD26 was higher in pfMSCs than in bmMSCs. Differentiation studies using osteogenic and adipogenic induction media (OM and AM, respectively) demonstrated that pfMSCs rapidly accumulated lipid droplets within 1 week of exposure to AM, while bmMSCs isolated from the same femur only formed lipid droplets after 3 weeks of AM treatment. Conversely, pfMSCs exposed to OM produced mineralized extracellular matrix (ECM) after 3 weeks, compared to 1 week for OM-treated bmMSCs. Vanadate (10 µM) added to AM resulted in a significant reduction in AM-induced intracellular lipid accumulation and expression of adipogenic gene markers (PPARγ2, aP2, adipsin) in both pfMSCs and bmMSCs. Pharmacological concentrations of glucocorticoids (1 µM) alone did not induce lipid accumulation in either bmMSCs or pfMSCs, but resulted in significant cell death in pfMSCs. Our findings demonstrate the existence of at least two fundamentally different MSC depots within the femur, and highlights the presence of MSCs capable of rapid adipogenesis within the proximal femur, an area prone to osteoporotic fractures. In addition, our results suggest that the increased bone marrow adiposity observed in GIO may not be solely due to direct effect of glucocorticoids on bone-derived MSCs, and that an increase in femur lipid content may also arise from increased adipogenesis in MSCs residing outside of the bone marrow niche.http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00108/fullAdipogenesisGlucocorticoidsMesenchymal Stem CellsBonedifferentiationosteoblast
spellingShingle Frans Alexander Jacobs
Hanel Sadie-Van Gijsen
Mari van de Vyver
William Frank Ferris
Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
Frontiers in Endocrinology
Adipogenesis
Glucocorticoids
Mesenchymal Stem Cells
Bone
differentiation
osteoblast
title Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
title_full Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
title_fullStr Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
title_full_unstemmed Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
title_short Vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone.
title_sort vanadate impedes adipogenesis in mesenchymal stem cells derived from different depots within bone
topic Adipogenesis
Glucocorticoids
Mesenchymal Stem Cells
Bone
differentiation
osteoblast
url http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00108/full
work_keys_str_mv AT fransalexanderjacobs vanadateimpedesadipogenesisinmesenchymalstemcellsderivedfromdifferentdepotswithinbone
AT hanelsadievangijsen vanadateimpedesadipogenesisinmesenchymalstemcellsderivedfromdifferentdepotswithinbone
AT marivandevyver vanadateimpedesadipogenesisinmesenchymalstemcellsderivedfromdifferentdepotswithinbone
AT williamfrankferris vanadateimpedesadipogenesisinmesenchymalstemcellsderivedfromdifferentdepotswithinbone